Skip to main content
. 2021 Dec 16:1–12. doi: 10.1159/000520221

Fig. 6.

Fig. 6

Summary of clinical and pathological characteristics in lethal COVID-19, dependent on RAASi-intake. Patients with RAASi-intake were observed to have higher viral loads, shorter hospitalization times (time till death) and significantly lower ACE/ACE2 ratios. A higher proportion of patients with RAASi-intake presented with exudative DAD, in line with the shorter hospitalization times. Original lung artwork by Servier Medical Art©, licensed under a Creative Commons Attribution 3.0 Unported License. COVID-19, coronavirus disease 2019; RAASi, renin-angiotensin-aldosterone system inhibitor; ACE/ACE2, angiotensin converting enzyme/angiotensin converting enzyme-2; DAD, diffuse alveolar damage.